×ðÁú¿­Ê±

EN
EN
  • ÓªÒµ×Éѯ

    Öйú£º

    Email: marketing@medicilon.com.cn

    ÓªÒµ×ÉѯרÏߣº400-780-8018

    £¨½öÏÞЧÀÍ×Éѯ £¬ÆäËûÊÂÒËÇ벦´ò´¨É³×ܲ¿µç»°£©

    ´¨É³×ܲ¿µç»°: +86 (21) 5859-1500

    ÍâÑó£º

    +1(781)535-1428(U.S.)

    0044 7790 816 954 (Europe)

    Email:marketing@medicilon.com

ÔÚÏßÁôÑÔ¡Á
µã»÷Çл»
Customer Center
¿Í»§ÖÐÐÄ

Éè¼ÆºÏ³ÉºÍÆÀ¹ÀÓÃÓÚÖÎÁÆÇ°ÏßÏÙ°©µÄCBPäå½á¹¹ÓòÒÖÖÆ¼Á¡£PKÆÀ¹À¡¢¸Î΢Á£ÌåÎȹÌÐԲⶨºÍCaco-2ÉøÍ¸ÐԲⶨͨ¹ý×ðÁú¿­Ê±¾ÙÐÐ

2023-07-05
|
»á¼ûÁ¿£º

Prostate cancer (PCa) is one of the most commonly diagnosed cancers and the leading cause of cancer mortalities in men. CREB (cyclic-AMP responsive element binding protein) binding protein (CBP) is a potential target for prostate cancer treatment. Researchers designed 1-(Indolizin-3-yl)ethan-1-ones as CBP bromodomain inhibitors for the treatment of prostate cancer.

Pharmacokinetic properties evaluation were analyzed by Medicilon.

Liver microsomal stability assay were performed at Medicilon.

Caco-2 permeability assay was analyzed by Medicilon.

46.png

Reference:

Qiuping Xiang, et al. Design, Synthesis, and Biological Evaluation of 1-(Indolizin-3-yl)ethan-1-ones as CBP Bromodomain Inhibitors for the Treatment of Prostate Cancer. J Med Chem. 2022 Jan 13;65(1):785-810. doi: 10.1021/acs.jmedchem.1c01864. 

Ïà¹ØÐÂÎÅ
¡Á
ËÑË÷ÑéÖ¤
µã»÷Çл»
¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿